John G. Ullman & Associates’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
Other funds holding HAE
John G. Ullman & Associates's HAE Position: Q3 2026 in Review
John G. Ullman & Associates reduced its Haemonetics (HAE) stake by 0.81% in Q3 2026, selling an estimated $9.31K and leaving 12,250 shares worth $1.29M. The position accounts for 0.17% of the portfolio, ranked #100.
John G. Ullman & Associates first reported a position in HAE in Q3 2025 and has held it in 5 quarters since. 358 funds tracked by Wall St. Rank hold HAE as of Q3 2026.
- John G. Ullman & Associates held 12,250 shares of Haemonetics worth $1.29M as of Q3 2026.
- John G. Ullman & Associates sold 100 Haemonetics shares in Q3 2026, an estimated $9.31K.
- Haemonetics made up 0.17% of John G. Ullman & Associates's portfolio in Q3 2026, its #100 holding.
- John G. Ullman & Associates first reported a position in Haemonetics in Q3 2025 and has held it in 5 quarters since.
- 358 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.
Based on John G. Ullman & Associates's 13F filing for Q3 2026, filed 4 Nov 2026.